EUVIMEDEUVIMED entdecken
Crossref

Pharmacotherapy of heart failure A.D. 2023. Expert opinion of Working Group on Cardiovascular Pharmacotherapy, Polish Cardiac Society

Jarosław D Kasprzak, Iwona Gorczyca-Głowacka, Maria Sobczak-Kaleta, Marcin Barylski, Jarosław Drożdż, Krzysztof J Filipiak, Agnieszka Kapłon-Cieślicka, Małgorzata Lelonek, Artur Mamcarz, Dorota Ochijewicz, Anna Ryś-Czaporowska, Katarzyna Starzyk und 3 weitere

Kardiologia Polska · 29.05.2023 · 81 (5) · 537-556

DOI: 10.33963/kp.a2023.0110 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Kardiologia Polska, online erschienen am 29.05.2023. Verfasst von Jarosław D Kasprzak und 14 weiteren Autor:innen. Beteiligte Einrichtung: 1st Department of Cardiology, Medical University of Lodz, Łódź, Poland. kasprzak@ptkardio.pl. Hauptthemen laut MEDLINE: Heart Failure. Die Arbeit wurde bisher 9-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heart failure (HF) remains one of the most common causes of hospitalization and mortality among Polish patients. The position of the Section of Cardiovascular Pharmacotherapy presents the currently applicable options for pharmacological treatment of HF based on the latest European and American guidelines from 2021-2022 in relation to Polish healthcare conditions. Treatment of HF varies depending on its clinical presentation (acute/chronic) or left ventricular ejection fraction. Initial treatment of symptomatic patients with features of volume overload is based on diuretics, especially loop drugs. Treatment aimed at reducing mortality and hospitalization should include drugs blocking the renin-angiotensin-aldosterone system, preferably angiotensin receptor antagonist/neprilysin inhibitor, i.e. sacubitril/valsartan, selected beta-blockers (no class effect - options include bisoprolol, metoprolol succinate, or vasodilatory beta-blockers - carvedilol and nebivolol), mineralocorticoid receptor antagonist, and sodium-glucose cotransporter type 2 inhibitor (flozin), constituting the 4 pillars of pharmacotherapy. Their effectiveness has been confirmed in numerous prospective randomized trials. The current HF treatment strategy is based on the fastest possible implementation of all four mentioned classes of drugs due to their independent additive action. It is also important to individualize therapy according to comorbidities, blood pressure, resting heart rate, or the presence of arrhythmias. This article emphasizes the cardio- and nephroprotective role of flozins in HF therapy, regardless of ejection fraction value. We propose practical guidelines for the use of medicines, profile of adverse reactions, drug interactions, as well as pharmacoeconomic aspects. The principles of treatment with ivabradine, digoxin, vericiguat, iron supplementation, or antiplatelet and anticoagulant therapy are also discussed, along with recent novel drugs including omecamtiv mecarbil, tolvaptan, or coenzyme Q10 as well as progress in the prevention and treatment of hyperkalemia. Based on the latest recommendations, treatment regimens for different types of HF are discussed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureHumansUnited StatesStroke VolumePolandProspective StudiesVentricular Function, LeftValsartanDrug CombinationsAngiotensin Receptor AntagonistsAminobutyrates

Stichwörter der Autor:innen

ACC/AHA/HFSA guidelinesESC guidelinesheart failurepharmacoeconomicspharmacotherapy

Substanzen

ValsartanDrug CombinationsAngiotensin Receptor AntagonistsAminobutyrates

Autor:innen und Institutionen

  • 1st Department of Cardiology, Medical University of Lodz, Łódź, Poland. kasprzak@ptkardio.pl.
  • Collegium Medicum, Jan Kochanowski University in Kielce, Kielce, Poland.
  • 1st Department of Cardiology, Medical University of Lodz, Łódź, Poland.
  • Department of Internal Diseases and Cardiac Rehabilitation, Medical University of Lodz, Łódź, Poland.
  • 2nd Department of Cardiology, Medical University Lodz, Łódź, Poland.
  • Institute of Clinical Sciences, Maria Sklodowska-Curie Medical Academy, Warszawa, Poland.

Zitieren

APA

Kasprzak, J. D., Gorczyca-Głowacka, I., Sobczak-Kaleta, M., Barylski, M., Drożdż, J., Filipiak, K. J., Kapłon-Cieślicka, A., Lelonek, M., Mamcarz, A., Ochijewicz, D., Ryś-Czaporowska, A., Starzyk, K., Szymański, F. M., Wełnicki, M., & Wożakowska-Kapłon, B. (2023). Pharmacotherapy of heart failure A.D. 2023. Expert opinion of Working Group on Cardiovascular Pharmacotherapy, Polish Cardiac Society. Kardiologia Polska, 81(5), 537-556. https://doi.org/10.33963/kp.a2023.0110

Vancouver

Kasprzak JD, Gorczyca-Głowacka I, Sobczak-Kaleta M, Barylski M, Drożdż J, Filipiak KJ, et al. Pharmacotherapy of heart failure A.D. 2023. Expert opinion of Working Group on Cardiovascular Pharmacotherapy, Polish Cardiac Society. Kardiologia Polska. 2023;81(5):537-556. doi:10.33963/kp.a2023.0110

BibTeX
@article{Kasprzak2023,
  author = {Kasprzak, Jarosław D and Gorczyca-Głowacka, Iwona and Sobczak-Kaleta, Maria and Barylski, Marcin and Drożdż, Jarosław and Filipiak, Krzysztof J and Kapłon-Cieślicka, Agnieszka and Lelonek, Małgorzata and Mamcarz, Artur and Ochijewicz, Dorota and Ryś-Czaporowska, Anna and Starzyk, Katarzyna and Szymański, Filip M and Wełnicki, Marcin and Wożakowska-Kapłon, Beata},
  title = {Pharmacotherapy of heart failure A.D. 2023. Expert opinion of Working Group on Cardiovascular Pharmacotherapy, Polish Cardiac Society},
  journal = {Kardiologia Polska},
  year = {2023},
  volume = {81},
  number = {5},
  pages = {537--556},
  doi = {10.33963/kp.a2023.0110}
}
Kostenlos starten →